Skip to content
value.today
Immunome Inc. logo

Immunome Inc.

Total raised
$40 M
6 rounds on record
Latest round
$11 M
Jun 2020
First round on record
Nov 2015
Today
Went public
See the company page

Immunome Inc. is listed today as Immunome, Inc.: market value, financials and filings are on its company page.

Funding rounds

6 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Immunome Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2021$27 MPrivate placement after listing$10 to $50 million

Immunome Inc.: Private sale, Apr 2021

Investors in this round

47 investors had bought by the notice of May 11, 2021: 47 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$410,000
Finders' fees
none
Paid to its own people
$1,300,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Corleen J Roche · Executive Officer
  • Dennis H Giesing · Executive Officer
  • Michael J Morin · Executive Officer
  • Purnanand Sarma · Executive Officer, Director
  • Sandra G Stoneman · Executive Officer
  • John J LaMattina · Director
  • Michael D Widlitz · Director
  • Michael J Lefenfeld · Director
  • Michael J Rapp · Director
  • Philip J Wagenheim · Director
  • Richard J Baron · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · New York, New YorkSold in all US states

Signed by Purnanand D. Sarma, Ph.D., President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2021. Read the notice at the SEC.

equity, optionsSEC
Jun 2020$11 MNo. 6$10 to $50 million

Immunome Inc.: Raise no. 6, Jun 2020

Investors in this round

49 investors had bought by the notice of Jun 16, 2020: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$11 M of $11 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Shares of Common Stock Issuable Upon Conversion of Series A Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$330,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Michael J Morin · Executive Officer, Director
  • Purnanand Sarma · Executive Officer, Director
  • I Wistar Morris · Director
  • John R LaMattina · Director
  • Michael D Rapoport · Director
  • Michael D Widlitz · Director
  • Michael R Lefenfeld · Director
  • Philip R Wagenheim · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Purnanand Sarma, Ceo. Source: SEC Form D, newest notice filed Jun 16, 2020. Read the notice at the SEC.

equity, optionsSEC
Nov 2019$9 MNo. 5$2 to $10 million

Immunome Inc.: Raise no. 5, Nov 2019

Investors in this round

35 investors had bought by the notice of Nov 19, 2019: 35 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $17 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Shares of common stock issuable upon conversion of Series A preferred stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$500,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David D. Kutcher · Executive Officer
  • Michael J. Morin · Executive Officer, Director
  • Purnanand Sarma · Executive Officer, Director
  • Scott D. Dessain · Executive Officer
  • I. Wistar Morris · Director
  • John R. LaMattina · Director
  • Michael D. Rapoport · Director
  • Michael D. Widlitz · Director
  • Michael R. Lefenfeld · Director
  • Philip R. Wagenheim · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Inclusive of proceeds from conversion of Notes. Series A financing expansion - to occur in multiple closings”

Signed by Purnanand Sarma, Ceo. Source: SEC Form D, newest notice filed Nov 19, 2019. Read the notice at the SEC.

equitySEC
Feb 2019$7 MNo. 4$2 to $10 million

Immunome Inc.: Raise no. 4, Feb 2019

Investors in this round

27 investors had bought by the notice of May 29, 2019: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $7 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$315,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David D. Kutcher · Executive Officer
  • Michael J. Morin · Executive Officer, Director
  • Philip R. Wagenheim · Executive Officer, Director
  • Scott D. Dessain · Executive Officer
  • I. Wistar Morris · Director
  • John R. LaMattina · Director
  • Michael D. Rapoport · Director
  • Michael D. Widlitz · Director
  • Michael R. Lefenfeld · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Philip R. Wagenheim, Secretary. Source: SEC Form D, newest notice filed May 29, 2019. Read the notice at the SEC.

debt, optionsSEC
May 2017$5 MNo. 3$2 to $10 million

Immunome Inc.: Raise no. 3, May 2017

Investors in this round

48 investors had bought by the notice of May 30, 2017: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$315,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David D. Kutcher · Executive Officer
  • Michael J. Morin · Executive Officer, Director
  • Philip R. Wagenheim · Executive Officer, Director
  • Scott D. Dessain · Executive Officer
  • Gregory R. Harriman · Director
  • I. Wistar Morris · Director
  • Michael D. Rapoport · Director
  • Michael D. Widlitz · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by David Kutcher, CFO and Treasurer. Source: SEC Form D, newest notice filed May 30, 2017. Read the notice at the SEC.

equity, optionsSEC
Jul 2016$5 MNo. 2$2 to $10 million

Immunome Inc.: Raise no. 2, Jul 2016

Investors in this round

27 investors had bought by the notice of Jul 14, 2016: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $12 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$756,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jane H. Hollingsworth · Executive Officer, Director
  • Michael J. Morin · Executive Officer
  • Gregory R. Harriman · Director
  • I. Wistar Morris · Director
  • Michael D. Rapoport · Director
  • Michael D. Widlitz · Director
  • Philip R. Wagenheim · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jane H. Hollingsworth, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 14, 2016. Read the notice at the SEC.

equitySEC
Nov 2015$4 MNo. 1$2 to $10 million

Immunome Inc.: Raise no. 1, Nov 2015

Investors in this round

18 investors had bought by the notice of Dec 2, 2015: 18 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 4 investors are named for Immunome Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$4 M of $9 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$472,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Pennsylvania

People named in the notice

  • Jane H. Hollingsworth · Executive Officer, Director
  • Joel Wistar Sussman · Executive Officer
  • Gregory R. Harriman · Director
  • I. Wistar Morris · Director
  • Michael D. Rapoport · Director
  • Michael D. Widlitz · Director
  • Philip R. Wagenheim · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Broadband Capital Management LLC · New York, New YorkSold in CT, FL, NC, NY, PA, WI

Signed by Jane H. Hollingsworth, Executive Chair and President. Source: SEC Form D, newest notice filed Dec 2, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Immunome, Inc., its revenue in fiscal 2025 came from these business segments: Single reportable segment $6.94 million (100%).

    Annual report (SEC XBRL) · Dec 2025

  • Immunome Inc. chose not to state its revenue in its newest notice of a funding round (May 2021).

    SEC Form D · May 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · May 2021

Products and services#

No products or services of Immunome Inc. are on record.

Investors#

4 named in official filings. Open an investor to see everything it has backed.

Investors in Immunome Inc.
InvestorKindAmountRoundRoleSource
I. Wistar Morris IIIPersonnot statednot statedHeld Series A preferred stock, 10% owner (Form 3, 2020)SEC Form 3
Michael LefenfeldPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2020)SEC Form 3
Michael RappPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2020)SEC Form 3
Michael WidlitzPersonnot statednot statedHeld Series A preferred stock, director (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 49 investors.

Largest shareholders today

Institutions holding Immunome, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immunome Inc.
NameRoleNamed in
Corleen J RocheExecutive officerMay 2021
Dennis H GiesingExecutive officerMay 2021
Michael J MorinExecutive officerMay 2021
Purnanand SarmaExecutive officerMay 2021
Sandra G StonemanExecutive officerMay 2021
David D. KutcherExecutive officerNov 2019
Michael J. MorinExecutive officerNov 2019
Scott D. DessainExecutive officerNov 2019
Philip R. WagenheimExecutive officerMay 2019
Jane H. HollingsworthExecutive officerJul 2016
Joel Wistar SussmanExecutive officerDec 2015
John J LaMattinaDirectorMay 2021
Michael D WidlitzDirectorMay 2021
Michael J LefenfeldDirectorMay 2021
Michael J RappDirectorMay 2021
Philip J WagenheimDirectorMay 2021
Purnanand SarmaDirectorMay 2021
Richard J BaronDirectorMay 2021
I Wistar MorrisDirectorJun 2020
John R LaMattinaDirectorJun 2020
Michael D RapoportDirectorJun 2020
Michael J MorinDirectorJun 2020
Michael R LefenfeldDirectorJun 2020
Philip R WagenheimDirectorJun 2020
I. Wistar MorrisDirectorNov 2019
John R. LaMattinaDirectorNov 2019
Michael D. RapoportDirectorNov 2019
Michael D. WidlitzDirectorNov 2019
Michael J. MorinDirectorNov 2019
Michael R. LefenfeldDirectorNov 2019
Philip R. WagenheimDirectorNov 2019
Gregory R. HarrimanDirectorMay 2017
Jane H. HollingsworthDirectorJul 2016

Went public since 2020. Its SEC number is that of a company listed on a stock exchange.